Inactive Instrument

Cryo-Cell International, Inc. Stock Other OTC

Equities

CCEL

US2288951088

Healthcare Facilities & Services

Sales 2024 * 31.78M Sales 2025 * 35.21M Capitalization 59.73M
Net income 2024 * - Net income 2025 * 1M EV / Sales 2024 * 1.88 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.7 x
P/E ratio 2024 *
246 x
P/E ratio 2025 *
61.4 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 26.32%
More Fundamentals * Assessed data
Dynamic Chart
Cryo-Cell International, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024 CI
Cryo-Cell International to Spin Off Celle Unit, Explore Strategic Alternatives; Shares Jump MT
Cryo-Cell to Explore Strategic Alternatives, Spin-Off Celle CI
Cryo-Cell International, Inc. agreed to Spin-Off Celle Corp. CI
Cryo-Cell International, Inc. Reports Earnings Results for the Full Year Ended November 30, 2023 CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011. CI
Cryo-Cell International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023 CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011. CI
Cryo-Cell International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023 CI
Cryo-Cell International, Inc.(NYSEAM:CCEL) added to Russell 3000E Value Index CI
Cryo-Cell International, Inc.(NYSEAM:CCEL) added to Russell Microcap Value Index CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011. CI
Cryo-Cell International, Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023 CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011. CI
Cryo-Cell International, Inc. Reports Earnings Results for the Full Year Ended November 30, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 60 11-07-31
Chief Executive Officer 61 11-07-31
Director of Finance/CFO 55 97-03-31
Members of the board TitleAgeSince
Chief Executive Officer 61 11-07-31
Chief Executive Officer 60 11-07-31
Director/Board Member 60 11-08-24
More insiders
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
More about the company